Last checked at 17 May 2017 07:00
Oncimmune Holdings PLC
17 May 2017
("Oncimmune" or the "Company")
GRANT OF OPTIONS
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, announces that on 16 May 2017, options over 13,339 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") were awarded to a member of UK staff under the Oncimmune Holdings Plc 2016 Unapproved & EMI Share Option Plan. The options are subject to the rules of the Oncimmune Holdings Plc 2016 Unapproved & EMI Share Option Plan and vest in five equal annual parts, the first fifth vesting on 8 January 2018 and each year thereafter for a further four years, subject to continued employment. The options are exercisable at 147.50 pence, being the mid-market closing price of the Ordinary Shares on 15 May 2017.
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Giles Balleny, Dominic Wilson
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708